Component

Human AP endonuclease 1 / APE1 / APEX1

Context-specific entity; species, compartment and exposure are stated on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Omitting MgCl2 abolished detectable APE1 incision in the 2023 control reactions.

    Mg2+ → Human AP endonuclease 1 / APE1 / APEX1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human APE1 delta-N38; standard reaction initiated with 2 mM MgCl2.
    limitations
    Does not prove myricetin inhibits by magnesium chelation or causes magnesium deficiency.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    The repair enzyme also has a mineral-dependent assay requirement.
    primary_references
    Characterizing inhibitors of human AP endonuclease 1. · 2023 · https://pubmed.ncbi.nlm.nih.gov/36652434/ · DOI 10.1371/journal.pone.0280526

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 676–682

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human APE1 delta-N38; standard reaction initiated with 2 mM MgCl2. · source_derived_draft · unverified_draft

    ## myricetin-ape1-magnesium The repair enzyme also has a mineral-dependent assay requirement. Omitting MgCl2 abolished detectable APE1 incision in the 2023 control reactions. Model: Human APE1 delta-N38; standard reaction initiated with 2 mM MgCl2. Limitations: Does not prove myricetin inhibits by magnesium chelation or causes magnesium deficiency. Evidence access: Primary full text Characterizing inhibitors of human AP endonuclease 1. · 2023 · https://pubmed.ncbi.nlm.nih.gov/36652434/ · DOI 10.1371/journal.pone.0280526
    Complete structured claim and evidence

  2. The 2009 screen reported potent myricetin inhibition of human APE1; radiotracer follow-up placed IC50 below 0.5 micromolar.

    Myricetin → Human AP endonuclease 1 / APE1 / APEX1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Purified enzyme and fluorescent/radiolabeled abasic-DNA incision assays.
    limitations
    Potency and target specificity were subsequently challenged by aggregation-controlled work; preserve this as a disputed result.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    An early study identified a candidate DNA-repair inhibitor.
    primary_references
    Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19484131/ · DOI 10.1371/journal.pone.0005740

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 652–658

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Purified enzyme and fluorescent/radiolabeled abasic-DNA incision assays. · source_derived_draft · unverified_draft

    ## myricetin-ape1-original An early study identified a candidate DNA-repair inhibitor. The 2009 screen reported potent myricetin inhibition of human APE1; radiotracer follow-up placed IC50 below 0.5 micromolar. Model: Purified enzyme and fluorescent/radiolabeled abasic-DNA incision assays. Limitations: Potency and target specificity were subsequently challenged by aggregation-controlled work; preserve this as a disputed result. Evidence access: Primary full text Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19484131/ · DOI 10.1371/journal.pone.0005740
    Complete structured claim and evidence

  3. In 2023, myricetin showed only weak APE1 inhibition at 0.33 mM with detergent/BSA, preventing an IC50 estimate; inhibition was much stronger without those additives.

    Myricetin → Human AP endonuclease 1 / APE1 / APEX1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human APE1 delta-N38; UHPLC product assay and dynamic light scattering.
    limitations
    Authors propose nonspecific aggregation as an explanation for earlier potency. This is not a demonstrated explanation for every target in this chapter.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    Controlling compound aggregation changed the conclusion.
    primary_references
    Characterizing inhibitors of human AP endonuclease 1. · 2023 · https://pubmed.ncbi.nlm.nih.gov/36652434/ · DOI 10.1371/journal.pone.0280526

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 660–666

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human APE1 delta-N38; UHPLC product assay and dynamic light scattering. · source_derived_draft · unverified_draft

    ## myricetin-ape1-reassessment Controlling compound aggregation changed the conclusion. In 2023, myricetin showed only weak APE1 inhibition at 0.33 mM with detergent/BSA, preventing an IC50 estimate; inhibition was much stronger without those additives. Model: Human APE1 delta-N38; UHPLC product assay and dynamic light scattering. Limitations: Authors propose nonspecific aggregation as an explanation for earlier potency. This is not a demonstrated explanation for every target in this chapter. Evidence access: Primary full text Characterizing inhibitors of human AP endonuclease 1. · 2023 · https://pubmed.ncbi.nlm.nih.gov/36652434/ · DOI 10.1371/journal.pone.0280526
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards